Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5338-5347

  Marlow, Laura A ^a   D'Innocenzi, Jaclyn ^a   Zhang, Yilin ^a   Rohl, Stephen D ^a   Cooper, Simon J ^a   Sebo, Thomas ^b   Grant, Clive ^b   McIver, Bryan ^b   Kasperbauer, Jan L ^b   Wadsworth, J Trad ^c,g   Casler, John D ^a   Kennedy, Pamela W ^h   Highsmith, W Edward ^b   Clark, Orlo ^d   Milosevic, Dragana ^b   Netzel, Brian ^b   Cradic, Kendall ^b   Arora, Shilpi ^e   Beaudry, Christian ^e   Grebe, Stefan K ^b   Silverberg, Marc L ^f   Azorsa, David O ^e   Smallridge, Robert C ^a   Copland, John A ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALKYLATING AGENT; GGTI 286; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; ROMIDEPSIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SHORT TANDEM REPEAT; THYROID CARCINOMA; UPREGULATION;

EID: 78650039981     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1421     Document Type: Article

References (17)

1. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44
2. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA 2009 Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res 69:1536-1544
3. Prendergast GC 2001 Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer 1:162-168
4. Alston-Roberts C, Barallon R, Bauer S, Butler J, Capes-Davis A, Dirks W, Elmore E; American Type Culture Collection Standards Development Organization Workgroup ASN-0002 2010 Cell line misidentification: the beginning of the end. Nat Rev Cancer 10:441-448
5. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341 (Pubitemid 352789529)
6. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58:460-470 (Pubitemid 43999794)
7. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Δ][Δ]CT method. Methods 25:402-408 (Pubitemid 34164012)
8. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207 (Pubitemid 41743711)
9. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK 2009 Mutant BRAFT1799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 94:5001-5009
10. Hamelers IH, Van Schaik RF, Sussenbach JS, Steenbergh PH 2003 17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor. Cancer Cell Int 3:10
11. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF 2003 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026
12. Zhong WB, Wang CY, Chang TC, Lee WS 2003 Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144:3852-3859 (Pubitemid 37088739)
13. Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS 2005 Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12:615-629
14. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB 2007 p53-Deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11:175-189 (Pubitemid 46209849)
15. Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM 2004 UCN-01-induced cell cycle arrest requires the transcriptional induction of p21waf1/cip1 by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signalregulated kinase pathway. Cancer Res 64:3629-3637
16. Lapenna S, Giordano A 2009 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566
17. Wang SH, Phelps E, Utsugi S, Baker Jr JR 2001 Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. Thyroid 11:725-731